
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


MannKind Corp (MNKD)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: MNKD (4-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -0.87% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.56B USD | Price to earnings Ratio 70.62 | 1Y Target Price 10 |
Price to earnings Ratio 70.62 | 1Y Target Price 10 | ||
Volume (30-day avg) 2121613 | Beta 1.28 | 52 Weeks Range 3.97 - 7.63 | Updated Date 03/30/2025 |
52 Weeks Range 3.97 - 7.63 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.07% | Operating Margin (TTM) 21.71% |
Management Effectiveness
Return on Assets (TTM) 9.12% | Return on Equity (TTM) - |
Valuation
Trailing PE 70.62 | Forward PE 29.59 | Enterprise Value 1377504460 | Price to Sales(TTM) 5.35 |
Enterprise Value 1377504460 | Price to Sales(TTM) 5.35 | ||
Enterprise Value to Revenue 4.82 | Enterprise Value to EBITDA 17.77 | Shares Outstanding 275777984 | Shares Floating 270675806 |
Shares Outstanding 275777984 | Shares Floating 270675806 | ||
Percent Insiders 2.06 | Percent Institutions 61.47 |
Analyst Ratings
Rating 4.8 | Target Price 9.8 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MannKind Corp

Company Overview
History and Background
MannKind Corp was founded in 1991. It's a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases. Early struggles led to restructuring, but recent focus on Afrezza and other pipeline drugs has improved its outlook.
Core Business Areas
- Inhaled Therapeutics: Development and commercialization of inhaled therapeutic products, primarily focusing on Afrezza for diabetes.
- Orphan Lung Diseases: Research and development of therapies for rare pulmonary diseases.
Leadership and Structure
Michael Castagna serves as the Chief Executive Officer. The company operates with a functional organizational structure, emphasizing research, development, and commercial operations.
Top Products and Market Share
Key Offerings
- Afrezza: Afrezza is an inhaled insulin product used to control blood sugar in adults with diabetes. Market share information is difficult to pinpoint precisely, but MannKind controls a small fraction of the total insulin market, but a larger share of rapid acting insulins. Competitors include Novo Nordisk (NovoLog), Eli Lilly (Humalog, Lyumjev), and Sanofi (Apidra). Afrezza generated a significant portion of MannKind's revenue and growing.
- Tyvaso DPI: MannKind partnered with United Therapeutics (UTHR) to manufacture and commercialize Tyvaso DPI, an inhaled dry powder formulation of treprostinil for pulmonary hypertension. Mannkind receives a percentage of the revenue from UTHR.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the diabetes and pulmonary disease segments, is characterized by intense competition, strict regulatory requirements, and continuous innovation.
Positioning
MannKind is a niche player focusing on inhaled therapies. Its competitive advantage lies in its Technosphere technology, which allows for rapid insulin absorption. This positions them well within the niche rapid acting insulin market. Their partnership with United Therapeutics provides them with increased income through revenue and manufacturing.
Total Addressable Market (TAM)
The total addressable market for diabetes treatments and pulmonary hypertension therapies is substantial, estimated in the tens of billions of dollars. MannKind, focuses on a specific segment, namely rapid-acting insulin for diabetes and inhaled therapies for pulmonary diseases, is well-positioned to capture a segment of this market.
Upturn SWOT Analysis
Strengths
- Technosphere technology (rapid drug absorption)
- Partnership with United Therapeutics (Tyvaso DPI)
- Focus on niche markets (inhaled therapies)
- Strong IP portfolio
Weaknesses
- History of financial instability
- Limited sales and marketing infrastructure (compared to larger competitors)
- Dependence on a few key products
- Smaller market share within the large insulin market
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships and collaborations
- Increasing adoption of inhaled therapies
- Growing prevalence of diabetes and pulmonary diseases
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial risks
- Patent expirations
- Pricing pressure from insurers and PBMs
Competitors and Market Share
Key Competitors
- NVO
- LLY
- SNY
Competitive Landscape
MannKind faces intense competition from established players in the insulin market. Its inhaled insulin offers a unique value proposition, but it must overcome challenges in market adoption and pricing.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Revenue growth has accelerated in recent years due to increased Afrezza sales and royalty income from Tyvaso DPI.
Future Projections: Analysts expect continued revenue growth driven by Afrezza adoption and pipeline development. Monitor the market and sales of Afrezza, along with new indication of treatments for orphan lung diseases.
Recent Initiatives: Focus on expanding Afrezza market reach, pursuing new clinical trials, and exploring partnerships for pipeline products.
Summary
MannKind Corp shows improving revenues and promising partnerships, particularly with the FDA approved drug Afrezza. Financial results show losses are still present but steadily decreasing. The company still needs to focus on overcoming marketing and commercial infrastructure challenges, in order to further increase adoption. Investors should continue to monitor revenue growth, cash flow, and market dynamics for the insulin rapid acting market.
Similar Companies
- NVO
- LLY
- SNY
- UTHR
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MannKind Corp
Exchange NASDAQ | Headquaters Danbury, CT, United States | ||
IPO Launch date 2004-07-28 | CEO & Director Dr. Michael E. Castagna Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 403 | Website https://www.mannkindcorp.com |
Full time employees 403 | Website https://www.mannkindcorp.com |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.